You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Congresses and Publications

Congress Materials

Access abstracts, posters, and presentations presented at the following congresses

June 2021

European Hematology Association (EHA)

European Hematology Association (EHA)

June 2021 (Virtual)

Abstracts

Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenstrӧm macroglobulinemia: matching-adjusted indirect comparisons Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study) Preliminary safety data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 Zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): long-term efficacy and safety results from a phase 2 study Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
May 2021

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

May 2021 (Virtual)

Abstracts

Examining longitudinal practice patterns in the use of anti-PD-1 and anti-PD-L1 inhibitors as first-line therapy in non-small cell lung cancer patients in the US Health related quality of life (HRQOL) review in patients with ovarian cancer: a systematic literature review (SLR) Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma
April 2021

American Association for Cancer Research (AACR)

American Association for Cancer Research (AACR)

April 2021 (Virtual)

Presentations

Results from RATIONALE 303: a global phase 3 study of tislelizumab vs docetaxel as second- or third-line therapy for patients with locally advanced or metastatic NSCLC Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)

Posters

A Fc-competent anti-human TIGIT blocking antibody BGB-A1217 elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models

Abstracts

A Fc-competent anti-human TIGIT blocking antibody BGB-A1217 elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models Results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)
March 2021

European Lung Cancer Congress (ELCC)

European Lung Cancer Congress (ELCC)

March 2021 (Virtual)

Posters

Neoadjuvant tislelizumab or placebo + platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non-small cell lung cancer: a phase 3 trial in progress

Abstracts

Neoadjuvant tislelizumab or placebo + platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non-small cell lung cancer (NSCLC): a phase 3 trial in progress
March 2021

Japanese Gastric Cancer Association (JGCA)

Japanese Gastric Cancer Association (JGCA)

March 2021 (Virtual)

Presentations

First-line tislelizumab + chemotherapy for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma

Abstracts

First-line tislelizumab + chemotherapy for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma
January 2021

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

January 2021 (Virtual)

Posters

A phase 2B, open-label, single-arm study of zanidatamab (ZW25) monotherapy in patients with advanced or metastatic HER2-amplified biliary tract cancer (BTC): HERIZON-BTC-01 study

Abstracts

A phase IIB, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers
See Full List of Congresses

Most Recent Publications

 Your ability to access these articles may depend on your or your institution's subscriptions to the journals.

See full list of publications

Search Publications and Congress Materials

This website houses a database of publications and congress materials from medical congresses around the world. Use our search engine below to access information pertinent to your search needs.

Clear All

Publications

 Your ability to access these articles may depend on your or your institution's subscriptions to the journals.

Publication Name
Author
Year
Disease State
Molecule
Loading publications, please wait... No publications found.
Showing [[ publicationsDisplayCount ]] of [[ publications.length ]]

Congresses

Material Type and Title
Congress
Year
Disease State
Molecule
Loading congresses, please wait... No congresses found.
Showing [[ countVisibleCongressDocs ]] of [[ congressDocuments.length ]]

BeiGene, Ltd. maintains the site for your personal information, education, and communication. Please feel free to browse the site. You may not, however, distribute, modify, transmit, reuse, repost or use the content of the site for public or commercial purposes, including the text and images, without BeiGene’s written permission.  
 
This is an online medical resource for scientific and clinical information. BeiGene makes no representation that the information in this site is appropriate for every country or region. If you choose to access this site, you are responsible for compliance with applicable local laws.